Luseogliflozin
 | |
| Clinical data | |
|---|---|
| Trade names | Lusefi |
| Other names | TS-071 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30O6S |
| Molar mass | 434.55 g·mol−1 |
| 3D model (JSmol) | |
| |
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus.[1][2] It was approved for use in Japan in 2014.[1] In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et. al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/dl), uric acid (-0.48mg/dl) and alanine aminotransferase (-4.11 IU/L) as compared to placebo, highlighting the beneficial impact on the different aspects of metabolic syndrome. [3]
References
[edit]- ^ a b Markham A, Elkinson S (June 2014). "Luseogliflozin: first global approval". Drugs. 74 (8): 945–50. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
- ^ Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. (September 2017). "Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study". Clinical Pharmacology in Drug Development. 6 (5): 439–447. doi:10.1002/cpdd.364. PMID 28783873.
- ^ Dutta D, Kadian J, Mahajan K, Dhall A, Sharma M (Mar 2023). "Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis". Diabetes Metab Syndr. 17 (3): 102742. doi:10.1016/j.dsx.2023.102742. PMID 36933330.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |